Trends in Food Science & Technology,
Journal Year:
2023,
Volume and Issue:
138, P. 178 - 198
Published: June 11, 2023
The
human
gut
hosts
complex
microbial
communities,
which
are
linked
to
health
and
disease.
microbiota
is
continuously
reshaped
by
multiple
environmental
factors,
especially
diet.
Gut
dysbiosis
may
promote
various
metabolic,
neurological,
intestinal,
cardiovascular
diseases,
even
tumor
development.
Probiotics
have
shown
promising
prophylactic,
mitigating,
or
curative
effects
when
use
as
nutrient
supplements
adjunctive
therapy.
These
beneficial
and/or
symptom
alleviation
often
accompanied
microbiome
metabolome
changes.
Differing
from
other
published
review
articles,
here
we
summarized
the
latest
knowledge
of
evidence-based
health-promoting
probiotics
scouring
literature
recent
animal
probiotic
intervention
studies.
To
elucidate
mechanisms
in
enhancing
intestinal
homeostasis,
barrier
function,
host
immunity,
through
modulating
its
metabolites.
Meanwhile,
also
discussed
challenges
data
analysis
clinical
research
comparison
between
laboratories,
provides
an
outlook
for
future
perspectives
applications
probiotics.
achieved
modulation.
Current
discussed.
Finally,
provided.
Journal of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: March 14, 2023
Abstract
Background
Gut
microbiota
modulation
has
been
demonstrated
to
be
effective
in
protecting
patients
against
detrimental
effects
of
anti-cancer
therapies,
as
well
improve
the
efficacy
certain
treatments.
Among
most
characterized
probiotics,
Lactobacillus
rhamnosus
GG
(LGG)
is
currently
utilized
clinics
alleviate
diarrhea,
mucositis
or
intestinal
damage
which
might
associated
with
several
triggers,
including
Clostridium
difficile
infections,
inflammatory
gut
diseases,
antibiotic
consumption,
chemotherapy
radiation
therapy.
Here,
we
investigate
whether
LGG
cell-free
supernatant
(LGG-SN)
exert
anti-proliferative
activity
toward
colon
cancer
and
metastatic
melanoma
cells.
Moreover,
assess
potential
adjuvant
effect
LGG-SN
combination
drugs.
Methods
alone
either
5-Fuorouracil
Irinotecan
was
used
treat
human
cell
lines.
Dimethylimidazol-diphenyl
tetrazolium
bromide
assay
employed
detect
cellular
viability.
Trypan
blue
staining,
anti-cleaved
caspase-3
anti-total
versus
PARP
western
blots,
annexin
V/propidium
iodide
flow
cytometry
analyses
were
death.
Flow
measurement
DNA
content
(with
propidium
staining)
together
qPCR
analysis
cyclins
expression
cycle.
Results
We
demonstrate
that
able
selectively
reduce
viability
cells
a
concentration-dependent
way.
While
does
not
any
on
control
fibroblasts.
In
cells,
reduction
apoptosis
induction,
but
mitotic
arrest
G2/M
phase
Additionally,
sensitizes
both
5-Fluorouracil
Irinotecan,
thereby
showing
positive
synergistic
action.
Conclusion
Overall,
our
results
suggest
may
contain
one
more
bioactive
molecules
sensitize
chemotherapeutic
Thus,
could
proposed
an
ideal
candidate
for
ground-breaking
integrated
approaches
oncology,
chemotherapy-related
side
overcome
resistance
relapse
issues,
thus
ameliorating
therapeutic
response
patients.
